€143.20
0.37% today
L&S, Jul 03, 07:39 pm CET
ISIN
GB0009895292
Symbol
AZN
Sector
Industry

AstraZeneca Share price

GBP120.20
-3.26 2.64% 1M
+14.46 13.67% 6M
+15.84 15.17% YTD
+18.72 18.44% 1Y
+39.09 48.19% 3Y
+61.95 106.35% 5Y
+88.58 280.12% 10Y
London, Closing price Wed, Jul 03 2024
-0.66 0.55%
ISIN
GB0009895292
Symbol
AZN
Sector
Industry

Key metrics

Market capitalization GBP187.36b
Enterprise Value GBP208.41b
PER (TTM) P/E ratio 37.22
EV/FCF (TTM) EV/FCF 30.95
EV/Sales (TTM) EV/Sales 5.50
P/S ratio (TTM) P/S ratio 4.94
P/B ratio (TTM) P/B ratio 6.10
Dividend yield 1.88%
Last dividend (FY23) GBP2.28
Sales growth (TTM) Sales growth 3.99%
Turnover (TTM) Turnover GBP37.89b
EBIT (operating result TTM) EBIT GBP6.62b
Free cash flow (TTM) Free cash flow GBP6.73b
Cash position GBP6.35b
EPS (TTM) EPS GBP3.25
P/E ratio expected 27.06
P/S ratio expected 4.58
EV/Sales expected 5.09
Show more

Create a Free Account to create an AstraZeneca alert.

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

AstraZeneca Share analysis

Analyst opinions

33 Analysts have issued a AstraZeneca forecast:

24x Buy
73%
8x Hold
24%
1x Sell
3%

Analyst opinions

33 Analysts have issued a AstraZeneca forecast:

Buy
73%
Hold
24%
Sell
3%

Financial data from AstraZeneca

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '24
+/-
%
37,892 37,892
4% 4%
100%
- Direct costs 9,926 9,926
20% 20%
26%
27,966 27,966
17% 17%
74%
- Selling and administrative expenses 8,761 8,761
31% 31%
23%
- Research and development costs 8,497 8,497
6% 6%
22%
10,707 10,707
15% 15%
28%
- Depreciation and amortization 4,092 4,092
13% 13%
11%
EBIT (operating result) EBIT 6,616 6,616
44% 44%
17%
Net profit 5,030 5,030
28% 28%
13%

Figures in millions GBP.

Don't miss a thing! We will send you all news about the AstraZeneca share directly to your mailbox free of charge.

If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.

AstraZeneca Share News

Positive
Seeking Alpha
20 minutes ago
Unfortunately, UK investors have had to suffer weak or negative capital gains in recent years to get those high yields. The good news is that the UK remains an attractive market for dividend investors. Don't forget that companies usually retain some of their earnings to fund expansion and growth, so dividends have (on average) grown ahead of inflation over the medium and long term,.
Positive
Proactive Investors
about 10 hours ago
Shares of Aptamer Group PLC (AIM:APTA) were up 12% after announcing a new collaboration with AstraZeneca PLC (LSE:AZN) to explore the use of Optimer technology for targeted delivery of siRNA, a type of genetic material used in therapies. Optimers are synthetic molecules designed to bind specifically to target cells, enhancing the delivery and effectiveness of treatments.
Neutral
InvestorPlace
one day ago
One of the greatest forces in wealth-building is the power of compounding. That is why every portfolio needs some set-it-and-forget-it stocks.
More AstraZeneca News

Company profile

AstraZeneca Plc is a holding company, which engages in the research, development, and manufacture of pharmaceutical products. Its pipeline are used for the following therapy areas: oncology, cardiovascular, renal, metabolism, and respiratory. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Head office United Kingdom
CEO Pascal Soriot
Employees 89,900
Founded 1992
Website www.astrazeneca.co.uk

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today